Naratriptan Orifarm (Naratriptan)

Naratriptan selectively stimulates 5‑HT1B and 5‑HT1D receptors in the brain, causing constriction of dilated cranial blood vessels and blocking the release of inflammatory neuropeptides, which together reduce migraine pain.

The dose of naratriptan is determined by the prescribing clinician based on individual patient factors and local prescribing guidelines. Patients should follow the exact dosage instructions provided by their healthcare professional.

The safety of naratriptan in pregnancy and lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their doctor before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naratriptan has a longer half‑life than some triptans, which can provide extended migraine relief with a single dose. Its side‑effect profile is similar to other agents in the class, but individual response varies, so clinicians may choose based on patient history and tolerability.

Store Naratriptan Orifarm at room temperature, below 25 °C, in the original blister pack or container. Keep it away from moisture and direct sunlight to maintain product stability.

Naratriptan Orifarm is taken orally, usually with a glass of water. It should be swallowed whole and not crushed or chewed. The medication is typically taken at the first sign of a migraine attack.

Serious risks include chest pain or tightness, cardiac arrhythmias, severe hypertension, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience any of these symptoms.

Individuals with uncontrolled cardiovascular disease, a history of stroke or transient ischemic attack, severe hepatic impairment, or those taking MAO inhibitors should avoid naratriptan. Contraindications are detailed in the prescribing information and should be reviewed by a healthcare professional.